Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study

Michele B. Kaufman, PharmD, BCGP  |  April 26, 2018

Initial results from an ongoing trial show that upadacitinib outperforms adalimumab in achieving ACR20 in patients with rheumatoid arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumabPsoriatic ArthritisRheumatoid Arthritis (RA)upadacitinib

elenabsl / shutterstock.com

Have We Reached the Limits of Clinical Classification?

Philip Seo, MD, MHS  |  April 26, 2018

There is an old adage that there are two types of people—lumpers and splitters. For some, people are easily categorized into liberal vs. conservative, Democrat vs. Republican, Donald Trump supporter vs. Hillary Clinton supporter. For others, everyone is a snowflake, and what makes us different is much more important than what makes us the same….

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:Classification Criteria

Rheumatology Coding Corner Question: RA Follow-Up with Imaging

From the College  |  April 26, 2018

History A 39-year-old woman returns for follow-up for her rheumatoid arthritis. She has positive rheumatoid factor, but no organ or systemic involvement. She has joint swelling and pain in her left hand, right elbow and right knee. Her pain is at an 8 on a 10-point scale. She states the pain is worse in the…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & CodingRheumatoid arthritis

Can Certain DMARDs Treat Dementia?

Larry Beresford  |  April 26, 2018

In the complex web of interactions between systemic inflammatory response, rheumatic disease and disease-modifying anti-rheumatic drugs (DMARDs), what is the potential for using rheumatologic therapies to treat other medical conditions linked to inflammation? Some medical researchers have looked at cardiac conditions, and others have examined the overlap with Alzheimer’s disease and other dementias. Positive effects…

Filed under:Uncategorized Tagged with:Alzheimer's DiseasedementiaDisease-modifying antirheumatic drugs (DMARDs)

PhuShutter / shutterstock.com

The FDA Approved Several New Rheumatology Drugs in 2017

Larry Beresford  |  March 18, 2018

SAN DIEGO—In a session at the 2017 ACR/ARHP Annual Meeting, Kam Nola, PharmD, MS, professor in the College of Pharmacy and vice chair in the Department of Pharmacy Practice at Lipscomb University in Nashville, Tenn., updated participants on new medications and new indications for rheumatology treatments and safety labeling changes approved by the U.S. Food…

Filed under:Drug UpdatesMeeting Reports Tagged with:abaloparatideACR/ARHP Annual MeetingAllopurinolbelimumabbrodalumabguselkumablesinuradMethotrexatesarilumabtocilizumab

DMARDs & Biologics Info for Rheumatology Nurses

Larry Beresford  |  March 17, 2018

SAN DIEGO—In a presentation on what rheumatology nurses should know in their daily practice about disease-modifying anti-rheumatic drugs (DMARDs) at the 2017 ACR/ARHP Annual Meeting Nov. 3–8, Jessica Farrell, PharmD, highlighted the importance of educating and counseling patients about the range of treatments and applications for rheumatologic conditions. Dr. Farrell, a clinical pharmacist at the…

Filed under:Biologics/DMARDsMeeting Reports Tagged with:ACR/ARHP Annual MeetingBiologicsDisease-modifying antirheumatic drugs (DMARDs)

Transcriptional Programming Research, & a Twist on CAR-T Cell Therapy

Thomas R. Collins  |  March 17, 2018

SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting this past November, an expert said researchers are making progress in identifying drugs that can correct problems with transcriptional programming, which, if perfected, could go a long way toward harnessing more fully the power of genetics knowledge and directing it toward patient care. The session also delved into…

Filed under:ConditionsMeeting Reports Tagged with:ACR/ARHP Annual Meetingpemphigus vulgarisT cell receptortranscriptional programming

Dealing with Simultaneous Cancer & Rheumatic Disease

Thomas R. Collins  |  March 17, 2018

SAN DIEGO—New insights into how scleroderma and myositis may be linked with cancer have led to intriguing questions that could impact patient care, experts said at the 2017 ACR/ARHP Annual Meeting in November. Understanding the relationship between cancer and rheumatic diseases is important because rheumatologists are seeing more and more patients with both diseases, and…

Filed under:Meeting ReportsSystemic Sclerosis Tagged with:ACR/ARHP Annual Meeting

The Latest Autoinflammatory Discoveries & Tips

Thomas R. Collins  |  March 17, 2018

SAN DIEGO—Since the identification of the autoinflammatory disease, familial Mediter­ranean fever (FMF), researchers have identified an alphabet soup of other auto­inflammatory diseases with genetic underpinnings, from PAPA (pyogenic arthritis with pyoderma gangrenosum and acne) to NIAID (NLRP1-associated autoinflammation with arthritis and dyskeratosis) to TRAPS (TNF receptor-associated periodic syndrome). The torrent of discoveries, brought about largely…

Filed under:ConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR/ARHP Annual Meetingadult Still's Diseaseanakinraautoinflammatory disease

ANCA-Associated Vasculitis Pathogenesis & Treatment Updates

Thomas R. Collins  |  March 17, 2018

SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting this past November, three researchers discussed the latest ANCA-associated vasculitis (AAV) research, including studies on AAV pathogenesis, therapies and remission maintenance. In the Philip Hench, MD, Memorial Lecture, J. Charles Jennette, MD, chair in pathology and laboratory medicine at the University of Carolina at Chapel Hill in Chapel…

Filed under:Meeting ReportsVasculitis Tagged with:ACR/ARHP Annual MeetingANCA-Associated VasculitisavacopanEGPAGPAmepolizumab

  • « Previous Page
  • 1
  • …
  • 51
  • 52
  • 53
  • 54
  • 55
  • …
  • 106
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences